Skip to content

Ketamine induces EEG oscillations that may aid anesthetic state but not dissociation monitoring

Shubham Chamadia, Jacob Gitlin, Jennifer Mekonnen, Breanna R. Ethridge, R. Ibala, Katia Colon, J. Qu, Oluwaseun Akeju

Clinical Neurophysiology October 1, 2021 DOI: 10.1016/j.clinph.2021.08.021 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Open-label study Peer reviewed
Sample size 15
Population Human subjects receiving ketamine anesthesia
Interventions Ketamine Midazolam
Dose 2 mg/kg
Topics Esketamine Ketamine
Key points Ketamine-induced electroencephalogram power and global coherence signatures track anesthetic state but not dissociation, as only midazolam, not electroencephalogram features, predicted dissociation scores.

Abstract

Objective: Ketamine is an anesthetic drug associated with dissociation. Decreased electroencephalogram alpha (8 to 13 Hz) and low-beta (13 to 20 Hz) oscillation power have been associated with ketamine-induced dissociation. We aimed to characterize surface electroencephalogram signatures that may serve as biomarkers for dissociation.

Methods: We analyzed data from a single-site, open-label, high-density surface electroencephalogram study of ketamine anesthesia (2mg/kg, n = 15). We assessed dissociation longitudinally using the Clinician Administered Dissociation States Scale (CADSS) and administered midazolam to attenuate dissociation and enable causal inference. We analyzed spectral power and global coherence with multitaper spectral methods. Mixed effects models were used to assess whether electroencephalogram power and global coherence signatures of ketamine could be developed into dissociation-specific biomarkers.

Results: Compared to baseline, ketamine unresponsiveness was associated with increased frontal power between 0.5 to 9.3 Hz, 12.2 to 16.6 Hz, and 24.4 to 50 Hz. As subjects transitioned into a responsive but dissociated state (mean CADSS ± SD, 22.1 ± 17), there was a decrease in power between 0.5 to 10.3 Hz and 11.7 to 50 Hz. Midazolam reduced dissociation scores (14.3 ± 11.6) and decreased power between 4.4 to 11.7 Hz and an increase in power between 14.2 to 50 Hz. Our mixed-effects model demonstrated a quadratic relationship between time and CADSS scores. When models (frontal power, occipital power, global coherence) were reanalyzed with midazolam and electroencephalogram features as covariates, only midazolam was retained.

Conclusions: Ketamine is associated with structured electroencephalogram power and global coherence signatures that may enable principled anesthetic state but not dissociation monitoring.

Significance: A neurophysiological biomarker for dissociation may lead to a better understanding of neuropsychiatric disorders.

Comparable studies

Other non-randomized and open-label trials on ketamine, most cited first.

Study Year Design Participants
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Intravenous arketamine for treatment-resistant depression: open-label pilot study Humans with treatment-resistant depression 2020 Open-label pilot trial n = 7
A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide. Hospitalized patients with Major Depressive Disorder and acute suicidal ideation and... 2024 Open label study n = 17
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Alcoholic patients 1997 Controlled clinical trial n = 211
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression Participants with DSM-IV-defined major depressive disorder and treatment-resistant... 2014 Pooled analysis of three clinical trials n = 97

Citations in the library

Explore topics